Search

Patient organizations

EHA greatly values the collaboration with patient organizations in a growing number of areas, from joint advocacy and a strong presence at the EHA Annual Congress – with a prominent place for the EHA-Patient Joint Symposium on policy and regulatory…

Read more

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Read more

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more

EHA-HKSH Hematology Tutorial on Lymphoid Malignancies

Dates: April 25-26, 2020 
Location: Hong Kong
Chairs: G Gaidano, J Gribben, MF Law

In 2020 EHA will co-organize the first Hematology Tutorial in Hong Kong, together with the Hong Kong Society of Haematology (HKSH).

Read more

EHA-Balkan Hematology Tutorial on Lymphoid Malignancies

“EHA and the Albanian Association of Hematology have jointly decided to postpone the first EHA-Balkan Hematology Tutorial in response to a request from the Albanian government to limit all international meetings.

Read more

Burnout - it doesn't just happen to someone else

Burnout - it doesn't just happen to someone else

By Dr. med.

Read more

COST Action ‘EuNet-INNOCHRON’

The European Cooperation in Science and Technology (COST) is an EU-funded, intergovernmental framework that aims to create pan-European research networks in all science fields and promote excellence, foster interdisciplinary research and empower young researchers and innovators.

Read more